KROS Earnings

Quarterly EPS
$-1.41
Q3 2024
$-1.14
Q4 2024
$3.66
Q1 2025
$-0.76
Q2 2025
$-0.18
Q3 2025
$-0.87
Q4 2025
$-1.21
Q1 2026
$-1.45
Q2 2026
Latest RevenueN/A
Latest Net Income-28710000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$1.450-28710000-100.0%-90.8%
Q1 2026-$1.21367.0K-23708000-99.8%-133.1%
Q4 2025-$0.87385.0K-23461000-87.3%+23.7%
Q3 2025-$0.1814.3M-7280000+3,575.8%+87.2%
Q2 2025-$0.7618.2M-30696000+49,002.7%+39.2%
Q1 2025$3.66211.2M148.5M+254,413.3%+402.5%
Q4 2024-$1.143.0M-46026000+2,027.3%+14.3%
Q3 2024-$1.41388.0K-52956000+4,750.0%-6.0%
Q2 2024-$1.2537.0K-45257000
Q1 2024-$1.2183.0K-43114000
Q4 2023-$1.33143.0K-40243000
Q3 2023-$1.338.0K-39440000
Keros Therapeutics (KROS) — Earnings